Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2013. The report details a specific share repurchase transaction executed on December 9, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 312,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,608.50 pence per share; lowest price paid was 1,595.00 pence per share.
- Treasury Holdings (Settled): 514,517,909 shares, representing 9.58% of total issued share capital.
- Treasury Holdings (Including Unsettled): 515,330,909 shares, representing 10.61% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,857,313,421 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 312,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior level to 10.61% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,857,313,421) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (10.61% including unsettled shares).
- Note that the filing does not contain operational or financial performance data for the period.